Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial-Reference-Cited by-同舟云学术

Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial

Published:2020-08 Issue:6 Volume:4 Page:984-996
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Moore Hunter B.¹,Barrett Christopher D.²³^ORCID,Moore Ernest E.¹⁴,Jhunjhunwala Rashi³,McIntyre Robert C.¹,Moore Peter K⁵,Wang Janice⁶,Hajizadeh Negin⁶,Talmor Daniel S.⁷,Sauaia Angela¹⁸,Yaffe Michael B.²³^ORCID

Affiliation:

1. Department of Surgery School of Medicine University of Colorado Denver Aurora CO USA

2. Departments of Biological Engineering and Biology Koch Institute for Integrative Cancer Research Center for Precision Cancer Medicine Massachusetts Institute of Technology Cambridge MA USA

3. Division of Acute Care Surgery, Trauma and Surgical Critical Care Department of Surgery Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA

4. Department of Surgery Ernest E Moore Shock Trauma Center at Denver Health Denver CO USA

5. Department of Medicine School of Medicine University of Colorado Denver Denver CO USA

6. Feinstein Institutes for Medical Research Northwell Health Manhasset NY USA

7. Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA

8. Colorado School of Public Health University of Colorado Denver Denver CO USA

Funder

Genentech

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12395

Reference87 articles.

1. A pathological report of three COVID‐19 cases by minimally invasive autopsies;Yao XH;Zhonghua Bing Li Xue Za Zhi,2020

2. Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet;Yang X;Respir Med,2020

3. Anticoagulant therapy for septic coagulopathy and disseminated intravascular coagulation: where do KyberSept and SCARLET leave us?

4. Clinical Characteristics of Coronavirus Disease 2019 in China

5. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19: A novel holistic systems biology approach to predict its molecular mechanisms (in vitro) and repurpose drugs;DARU Journal of Pharmaceutical Sciences;2023-08-19

2. Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19;Research and Practice in Thrombosis and Haemostasis;2023-08

3. Fibrinolysis in COVID-19: Impact on Clot Lysis and Modulation of Inflammation;Current Drug Targets;2022-12

4. Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS;Journal of Intensive Care;2022-07-30

5. MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study;Research and Practice in Thrombosis and Haemostasis;2022-02